Brainlab AG and Dalhousie University, Atlantic Canada’s leading research-intensive university, have entered into an exclusive intellectual property license agreement for integration with next-generation radiosurgery software.

RefleXion Medical, a medical equipment company developing the first biology-guided radiotherapy system for targeted, personalized cancer treatment, announced that it has closed a $46 million Series B round of funding.

The American College of Radiology (ACR), as a member of a coalition of leading medical societies, provided peripheral arterial disease (PAD) treatment recommendations to the Medicare Evidence Development Coverage Advisory Committee (MEDCAC).

Siemens, teamplay, imaging analytics software
Analytics: The Next Big Health IT Undertaking

With all areas of healthcare now migrating to electronic medical record (EMR) platforms, the data they contain can be mined to use increasingly sophisticated analytics software. This includes pulling information to improve department or hospital management, quality assurance to boost outcomes and efficiency, and even the ability to identify patients who are ideal referrals for new clinical programs such as low-dose lung computed tomography (CT) cancer screenings, or candidates for peripheral artery disease revascularization. 

As chronic traumatic encephalopathy (CTE) stands in the national spotlight for high impact sports, the University of California, Irvine has partnered with Toshiba America Medical Systems Inc. for a first-of-its-kind study of cerebral microbleeds (CMB) in high school football players as a potential precursor to CTE.

Physicians have begun treating patients with the Mevion S250 proton therapy system at The Marjorie and Leonard Williams Center for Proton Therapy at UF Health Cancer Center-Orlando Health in Florida.

Focal Therapeutics, makers of the three-dimensional BioZorb implant used in breast conservation therapy, announced it has launched BioZorb LP.

The intersection between PET/CT and radiation therapy is widening. And it is doing so in unanticipated ways.

The global market for contrast media is set to rise from just over $4.3 billion in 2015 to over $6 billion by 2022, according to research and consulting firm GlobalData. This represents a compound annual growth rate of 4.9 percent.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now